Supplementary Figure S3 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Peters S., Angevin E., Alonso-Gordoa T., Rohrberg K., Melero I., Mellado B., Perez-Gracia J-L., Tabernero J., Adessi C., Boetsch C., Watson C., Dal Porto J., Dejardin D., Del Nagro C., Nicolini V., Evers S., Klein C., Leutgeb B., Pisa P., Rossmann E., Saro J., Umana P., Charo J., Teichgräber V., Steeghs N.
<p>Supplementary Figure S3. Efficacy of IL-2v alone and in combination with anti-PD-L1 in A, Wild-type C57BL/6 mice and B, B-cell deficient C57BL/6 mice. IL-2v, interleukin-2 variant; PD-L1, programmed death-ligand 1.</p>